Ipamorelin vs Hexarelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: Examorelin, HEX
Hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or GHRP) that pushes the pituitary to release growth hormone. What makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. It is a research compound, not an approved drug, and almost all of the heart data is from animals.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Ipamorelin | Hexarelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | Hexarelin acts through two different receptors, which is the key to understanding it. The first is the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor in the pituitary, which is how it triggers growth hormone release. The second is CD36, a scavenger receptor found on heart muscle cells and small blood vessels, and this is where its cardioprotective story lives. Activating CD36 in the heart has been shown to improve coronary flow and protect heart tissue from ischemia (low oxygen) and reperfusion injury, and crucially these effects still happen in growth-hormone-deficient animals, proving the heart benefit is separate from the GH benefit. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 100-200 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks typical | 4-8 weeks (desensitization occurs) |
| Best Time to Take | Before bed or morning (fasted) | Morning and before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | The growth hormone-releasing effect of hexarelin is well established in humans from older endocrine research, but the exciting cardiovascular claims are still mostly preclinical. The landmark mechanistic work (Circulation Research, 2002) identified CD36 as the receptor through which growth hormone-releasing peptides act on the heart, and follow-up rodent studies showed hexarelin improves left ventricular function and protects cardiomyocytes from ischemia-reperfusion injury, in one case through interleukin-1 signaling (2017). A 2014 review in the Annals of the New York Academy of Sciences and a 2017 PMC review both lay out a plausible cardioprotective case. But here is the honest part: there are no large modern human trials showing hexarelin treats or prevents heart disease in people, and a known limitation is rapid tolerance, the GH response fades with continued use. So the cardiac angle is genuinely interesting biology, not an established therapy. |
Frequently Asked Questions: Ipamorelin vs Hexarelin
What is the difference between Ipamorelin and Hexarelin?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. Hexarelin is a growth hormone peptide that hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or ghrp) that pushes the pituitary to release growth hormone. what makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. it is a research compound, not an approved drug, and almost all of the heart data is from animals. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or Hexarelin?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while Hexarelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and Hexarelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and Hexarelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.